Work Here?
About Natera
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Total Funding
$149.9M
Headquarters
Austin, Texas
Founded
2004
Overview
Company Historically Provides H1B Sponsorship
Natera focuses on genetic testing and diagnostics, utilizing cell-free DNA (cfDNA) testing to detect molecular residual disease (MRD) in cancer patients and assess organ health for transplant patients. Their offerings include the Signatera test for cancer and Panorama NIPT for prenatal screening, with a strong emphasis on personalized genetic counseling. Natera stands out by providing a wide range of specialized testing services directly to healthcare providers and patients, often reimbursed by insurance. The company's goal is to improve patient care and health outcomes through advanced genetic testing solutions.
Simplify's Take
What believers are saying
- Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
- Growing personalized medicine trend enhances need for Natera's customized genetic tests.
- Expansion of telehealth services aligns with Natera's remote genetic counseling offerings.
What critics are saying
- Allegations of deceptive practices could harm Natera's reputation and lead to legal issues.
- New Prospera Heart features may face adoption challenges without independent validation.
- Ongoing legal investigations could result in financial penalties affecting Natera's stability.
What makes Natera unique
- Natera's Signatera test offers significant lead time in detecting cancer recurrence.
- Prospera Heart test integrates Donor Quantity Score for enhanced transplant rejection detection.
- Panorama NIPT uniquely determines fetal RhD status, aiding in prenatal care.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$149.9M
Below
Industry Average
Funded Over
10 Rounds
Lightspeed Venture Partners
Founders FundBenefits
Flexible medical plans
Investment options
Time off
Workplace perks
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 10%AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m
Alpha DNA Investment Management LLC invests $505,000 in Natera, Inc. (NASDAQ:NTRA).
Delap Wealth Advisory LLC makes new $454,000 Investment in Natera, Inc. (NASDAQ:NTRA).
In other recent news, Natera Inc. has launched the DECIPHER trial for gastroesophageal adenocarcinoma (EGC) treatment, utilizing its molecular residual disease (MRD) test, Signatera.
Donor Quantity Score (DQS) technique is unique to Natera, improving detection of both acute cellular rejection and antibody-mediated rejectionAUSTIN, Texas, June 17, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant patients.Traditionally, donor-derived cell-free DNA (dd-cfDNA) tests have reported rejection risk based only on the fraction of dd-cfDNA in the blood vs. the total cfDNA (dd-cfDNA %). This fraction can be confounded by fluctuations in the amount of background total cfDNA (the denominator), which are sometimes caused by factors unrelated to the health of the transplant, including infection, surgery, or chemotherapy.Prospera Heart now incorporates a second metric – the DQS – that normalizes for the background total cfDNA. Prospera Heart with DQS combines the traditional donor fraction and the new DQS into a two-threshold algorithm, delivering a single result with more accurate risk assessment for both antibody mediated rejection (AMR) and acute cellular rejection (ACR)."Over the last two decades, Natera has pioneered cfDNA testing across women’s health, oncology, and transplant medicine," said Michael Olymbios, M.D., Medical Director, Heart Transplant. "Our extensive experience with cfDNA and Natera’s culture of continuous innovation drove us to further refine Prospera Heart by introducing this two-threshold algorithm to better serve the transplant community."A study performed at the University of Utah and the University of California San Diego showed that incorporating DQS enhanced the performance of Prospera Heart in screening for biopsy-proven active rejection
Natera is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Natera
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Total Funding
$149.9M
Headquarters
Austin, Texas
Founded
2004
Natera is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today